Agenus Inc. (AGEN) Receives Consensus Rating of “Hold” from Analysts
Agenus Inc. (NASDAQ:AGEN) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $5.81.
Several brokerages have commented on AGEN. Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Wednesday, October 25th. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of Agenus in a research report on Friday, August 4th. ValuEngine upgraded shares of Agenus from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Finally, BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th.
Shares of Agenus (AGEN) opened at $3.73 on Friday. Agenus has a 1 year low of $3.20 and a 1 year high of $5.91. The company has a current ratio of 1.55, a quick ratio of 3.36 and a debt-to-equity ratio of -2.39.
Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, hitting the consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $5.91 million. The business’s quarterly revenue was down 24.4% on a year-over-year basis. equities analysts expect that Agenus will post -1.19 earnings per share for the current year.
In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were acquired at an average cost of $3.55 per share, for a total transaction of $355,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.60% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Agenus by 5.2% in the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock worth $13,805,000 after buying an additional 174,162 shares in the last quarter. Artal Group S.A. boosted its position in shares of Agenus by 25.0% in the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock worth $11,025,000 after buying an additional 500,000 shares in the last quarter. Northern Trust Corp boosted its position in shares of Agenus by 4.1% in the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock worth $3,682,000 after buying an additional 37,239 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Agenus by 3,447.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock worth $2,539,000 after buying an additional 654,351 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Agenus by 12.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock worth $2,724,000 after buying an additional 70,000 shares in the last quarter. Institutional investors and hedge funds own 39.56% of the company’s stock.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.